Amgen Inc. (AMGN)
After hours:
| Previous Close | 316.79 |
| Open | 314.63 |
| Bid | 314.62 x 100 |
| Ask | 315.02 x 100 |
| Day's Range | 310.76 - 316.14 |
| 52 Week Range | 211.71 - 329.72 |
| Volume | |
| Avg. Volume | 2,784,132 |
| Market Cap | 168.827B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 45.02 |
| EPS (TTM) | 6.99 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 9.00 (2.86%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | 316.85 |
PR NewswireFDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verificatio
ZacksAmgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
- PR Newswire
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief
